Title of article
Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
Author/Authors
Boeckx، نويسنده , , Carolien and Op de Beeck، نويسنده , , Ken and Wouters، نويسنده , , An and Deschoolmeester، نويسنده , , Vanessa and Limame، نويسنده , , Ridha and Zwaenepoel، نويسنده , , Karen and Specenier، نويسنده , , Pol and Pauwels، نويسنده , , Patrick and Vermorken، نويسنده , , Jan B. and Peeters، نويسنده , , Marc and Van Camp، نويسنده , , Guy and Baay، نويسنده , , Marc and Lardon، نويسنده , , Filip، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2014
Pages
13
From page
365
To page
377
Abstract
Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Our microarray results suggest that “resistant” cells still exhibit RAS–MAPK pathway signaling contributing to drug resistance, as witnessed by low expression of DUSP5 and DUSP6, negative regulators of ERK1/2, and increased expression of AURKB, a key regulator of mitosis. Therefore, interrupting the RAS–MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC.
Keywords
Cetuximab resistance , Dual-specificity phosphatase 5 and 6 , Aurora kinase B , NanoPro 1000 , Anti-EGFR therapy , Head and neck squamous cell carcinoma
Journal title
Cancer Letters
Serial Year
2014
Journal title
Cancer Letters
Record number
1825253
Link To Document